Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...

Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst ...

Headquartered in Foster City, California, Gilead Sciences, Inc. (GILD) is a prominent biopharmaceutical company with a market ...

Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. Gilead is expected to post earnings of $1.62 ...

GILD's full-year Zacks Consensus Estimates ... these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a ...

Needham analyst Joseph Stringer has maintained their neutral stance on GILD stock, giving a Hold rating today ... Barclays also maintained a Hold rating on the stock with a $95.00 price target.

Maxim downgraded Gilead (GILD) to Hold from Buy. The stock has appreciated significantly following a pullback in the first half of the year, ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.21% of ...

Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements. For the current quarter, Gilead is expected to ...

If an investor was to purchase shares of GILD stock at the current price level of $89.05/share, and then sell-to-open that call contract as a "covered call," they are committing to sell the stock ...

Deadly fungi including Candida auris have been spreading. Gilead and Merck are two pharma stocks worth owning amidst fungal ...